JP2024525559A5 - - Google Patents

Info

Publication number
JP2024525559A5
JP2024525559A5 JP2024500220A JP2024500220A JP2024525559A5 JP 2024525559 A5 JP2024525559 A5 JP 2024525559A5 JP 2024500220 A JP2024500220 A JP 2024500220A JP 2024500220 A JP2024500220 A JP 2024500220A JP 2024525559 A5 JP2024525559 A5 JP 2024525559A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
ratio
treatment
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073576 external-priority patent/WO2023283650A1/en
Publication of JP2024525559A publication Critical patent/JP2024525559A/ja
Publication of JP2024525559A5 publication Critical patent/JP2024525559A5/ja
Pending legal-status Critical Current

Links

JP2024500220A 2021-07-09 2022-07-08 アルツハイマー病治療用バイオマーカー Pending JP2024525559A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163220434P 2021-07-09 2021-07-09
US63/220,434 2021-07-09
US202163203444P 2021-07-22 2021-07-22
US63/203,444 2021-07-22
US202163263255P 2021-10-29 2021-10-29
US63/263,255 2021-10-29
US202163263928P 2021-11-11 2021-11-11
US63/263,928 2021-11-11
US202163264551P 2021-11-24 2021-11-24
US63/264,551 2021-11-24
US202263306028P 2022-02-02 2022-02-02
US63/306,028 2022-02-02
US202263269372P 2022-03-15 2022-03-15
US63/269,372 2022-03-15
US202263364618P 2022-05-12 2022-05-12
US63/364,618 2022-05-12
PCT/US2022/073576 WO2023283650A1 (en) 2021-07-09 2022-07-08 Biomarkers for alzheimer's disease treatment

Publications (2)

Publication Number Publication Date
JP2024525559A JP2024525559A (ja) 2024-07-12
JP2024525559A5 true JP2024525559A5 (cg-RX-API-DMAC7.html) 2025-07-16

Family

ID=83232761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500220A Pending JP2024525559A (ja) 2021-07-09 2022-07-08 アルツハイマー病治療用バイオマーカー

Country Status (11)

Country Link
US (1) US20250163135A1 (cg-RX-API-DMAC7.html)
EP (1) EP4367516A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525559A (cg-RX-API-DMAC7.html)
KR (1) KR20240033017A (cg-RX-API-DMAC7.html)
AU (1) AU2022307687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225302A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000063A1 (cg-RX-API-DMAC7.html)
IL (1) IL309468A (cg-RX-API-DMAC7.html)
MX (1) MX2023015183A (cg-RX-API-DMAC7.html)
TW (1) TW202317192A (cg-RX-API-DMAC7.html)
WO (1) WO2023283650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076808A (zh) 2022-09-23 2025-05-30 卫材R&D管理有限公司 减少与神经退行性疾病相关的神经退行性变的方法
WO2025019457A1 (en) * 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025260029A1 (en) 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
CN118777453B (zh) * 2024-06-25 2025-04-08 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
PT4121007T (pt) 2020-03-20 2025-09-25 Eisai R&D Man Co Ltd Formulações de anticorpo de protofibrila de péptido anti-beta amiloide de concentração alta e métodos de uso das mesmas
CA3172451A1 (en) * 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Similar Documents

Publication Publication Date Title
Bachurin et al. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention
JP2025506389A5 (cg-RX-API-DMAC7.html)
JP2022553329A (ja) アルツハイマー病を治療するための抗ベータ-アミロイド抗体
US20220402979A1 (en) Biomarkers and treatments of alzheimer's disease and mild cognitive impairment
AU2022206461A1 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
Panza et al. Passive tau-based immunotherapy for tauopathies
JP2020515639A (ja) 進行性核上性麻痺の処置のためのPPARγアゴニスト
JP2024525559A (ja) アルツハイマー病治療用バイオマーカー
TW202430554A (zh) 使用tau PET水平之治療方法
KR20240142535A (ko) P-tau181 수준을 사용한 치료 방법
KR102776048B1 (ko) 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물
Luca et al. A Phase 1 single-ascending-dose trial in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous pnt001, a novel mid-domain tau antibody targeting cis-pT231 tau
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
EP4583851A1 (en) Scyllo-inositol in combination with immunotherapeutics for the treatment of alzheimer's disease
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
JP2024540294A5 (cg-RX-API-DMAC7.html)
TW202313111A (zh) 治療阿茲海默症之方法
TW202325728A (zh) 治療阿茲海默症之方法
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
Shim et al. An autopsy-proven case-based review of autoimmune encephalitis
RU2024103015A (ru) Биомаркеры для лечения болезни альцгеймера
RU2024125461A (ru) Способы лечения с применением уровня P-TAU181
US20230218604A1 (en) PPARy AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
RU2025139087A (ru) Способы лечения с применением антитела к протофибриллам белка а-бета
WO2022251048A1 (en) Anti-amyloid beta antibodies and uses thereof